Ultragenyx Pharmaceutical Inc. has recently reported a significant investment from State Street Corporation and SSGA Funds Management, Inc. According to a Schedule 13G filing made on November 10, 2026, these two firms now hold a combined 7.6% of Ultragenyx’s common stock. This investment is notable as it reflects growing institutional interest in the pharmaceutical preparations sector.
Ultragenyx, a leader in the development of innovative medicines for rare diseases, is positioned to benefit from the backing of these prominent financial institutions. The investment not only strengthens Ultragenyx's financial standing but also enhances its strategic opportunities in a competitive landscape.
Background
Ultragenyx Pharmaceutical Inc. is classified under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is listed on the Nasdaq under the ticker symbol RARE. It is recognized as a large accelerated filer and has been active in filing various forms with the SEC, including recent reports such as a 10-Q and multiple Schedule 13G filings.
What the Filing Says
The Schedule 13G filing reveals that State Street Corporation beneficially owns 7,538,078 shares of Ultragenyx, while SSGA Funds Management, Inc. holds 5,318,630 shares. The filing states, "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of changing or influencing the control of the issuer." This indicates that the investment is primarily for financial purposes rather than a strategic takeover.
Impact
This investment could significantly affect Ultragenyx's operations and market perception. With State Street and SSGA as major stakeholders, the company may gain increased credibility and support in its future endeavors. Additionally, this move could prompt competitors in the pharmaceutical preparations sector to reevaluate their strategies and market positions.
What's Next
The filing does not specify what happens next regarding the investment or any potential strategic initiatives that Ultragenyx may undertake as a result of this new stake.
Read Next
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction
Orchestra BioMed CFO Acquires Shares in Recent Filing
Upwork CFO Erica Gessert Reports Major Stock Transactions




